News - Cardio-vascular

Filter

Current filters:

Cardio-vascular

Popular Filters

40 to 64 of 519 results

Merck starts roll-out of BLA for MK-3475; vorapaxar FDA panel review

Merck starts roll-out of BLA for MK-3475; vorapaxar FDA panel review

14-01-2014

US drug giant Merck & Co says it has started a rolling submission to the US Food and Drug Administration…

Cardio-vascularMerck & CoMK-3475North AmericaOncologyPharmaceuticalRegulationUSAvorapaxarZontivity

Daiichi Sankyo files Savaysa for US approval; collaborates with Virtici and Celdara Medical

Daiichi Sankyo files Savaysa for US approval; collaborates with Virtici and Celdara Medical

10-01-2014

Japanese drug major Daiichi Sankyo has filed a New Drug Application for its investigational, oral, once-daily…

Cardio-vascularCeldara MedicalDaiichi SankyoedoxabanNorth AmericaPharmaceuticalRegulationResearchSavaysaUSAVirtici

Japan to investigate Novartis promotion of Diovan; US allegation over Exjade

Japan to investigate Novartis promotion of Diovan; US allegation over Exjade

10-01-2014

Swiss drug major Novartis faced two problems yesterday, when the Japanese Ministry of Health Labor and…

Asia-PacificCardio-vascularDiovanExjadeHematologyLegalMarkets & MarketingNorth AmericaNovartisPharmaceuticalUSA

Nanomedicines market to reach $177.6 billion globally in 2019

08-01-2014

The global market for nanomedicine was valued at $78.54 billion in 2012 and is expected to reach a value…

BiotechnologyCardio-vascularGlobalMarkets & MarketingOncology

Daiichi Sankyo submits edoxaban application to the EMA for stroke prevention

Daiichi Sankyo submits edoxaban application to the EMA for stroke prevention

08-01-2014

Japanese drug major Daiichi Sankyo (TYO: 4568) has submitted a Marketing Authorization Application to…

Asia-PacificCardio-vascularDaiichi SankyoedoxabanPharmaceuticalRegulation

Capricor Therapeutics and Janssen collaborate on cell therapy program

Capricor Therapeutics and Janssen collaborate on cell therapy program

07-01-2014

California, USA-based Capricor Therapeutics says it has executed a collaboration agreement and exclusive…

BiotechnologyCAP-1002Capricor TherapeuticsCardio-vascularJanssen BiotechJohnson & JohnsonLicensing

Nissan Chemical and Kowa to sue generic drugmakers over Livalo patent infringements

30-12-2013

With the commencement this year of manufacturing and selling generic copies of the hypercholesterolemia…

Asia-PacificCardio-vascularGenericsKowaLegalLivaloNissan ChemicalPatents

AstraZeneca and Shionogi settle Crestor arbitration

AstraZeneca and Shionogi settle Crestor arbitration

26-12-2013

Anglo-Swedish drug major AstraZeneca revealed yesterday (December 26) the full resolution of arbitration…

Asia-PacificAstraZenecaCardio-vascularCrestorGlobalLicensingPharmaceuticalShionogi

Atherothrombotic diseases market to grow to $47 billion in 2022

Atherothrombotic diseases market to grow to $47 billion in 2022

23-12-2013

The launch of numerous add-on therapies in the atherothrombotic diseases market (incorporating pharmacotherapies…

AstraZenecaBayerBrilintaCardio-vascularEli LillyevacetrapibGlobalMarkets & MarketingPharmaceuticalXarelto

Sanofi to collaborate with the ACC to recruit patients for alirocumab clinical trial

Sanofi to collaborate with the ACC to recruit patients for alirocumab clinical trial

19-12-2013

French drug major Sanofi (Euronext: SAN) and Regeneron Pharmaceuticals (Nasdaq: REGN) have announced…

Cardio-vascularPharmaceuticalResearchSanofiUSA

Amgen reports positive results from Phase III trial of evolocumab for high cholesterol

Amgen reports positive results from Phase III trial of evolocumab for high cholesterol

18-12-2013

USA-based biotech company Amgen (Nasdaq: AMGN) has revealed positive top-line Phase III results for its…

AmgenBiotechnologyCardio-vascularevolocumabResearchUSA

Forest Laboratories announces new appointments to its executive team

16-12-2013

New York-based pharmaceutical company Forest Laboratories (NYSE: FRX) has announced new appointments…

Anti-viralsBoardroomCardio-vascularCNS DiseasesForest LaboratoriesGastro-intestinalsPharmaceuticalRespiratory and PulmonaryUSA

Catalyst-rich period ahead for key trial results from BioLineRx

09-12-2013

Israeli drug developer BioLineRx is entering a catalyst-rich phase over the next 12 months, which will…

Anti-viralsBioLineRxBL-1040BL-8020BL-8040Cardio-vascularFinancialOncologyPharmaceuticalResearch

Benefits of Kogenate/Helixate NexGen outweigh risks, says EMA unit

Benefits of Kogenate/Helixate NexGen outweigh risks, says EMA unit

08-12-2013

The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has reviewed the…

BayerCardio-vascularCSL BehringCSL LimitedEuropeHelixateHematologyKogenatePharmaceuticalRegulation

Modest growth forecast for global CD market

02-12-2013

The global market for cardiovascular disease - comprised of heart failure, myocardial infarction and…

AstraZenecaAZD6140BAY81-8781BayerCardio-vascularLCZ696Markets & MarketingNovartisPharmaceuticalPricingserelaxin

CSL presents positive data for potential new heart attack therapy

28-11-2013

Australian blood products and vaccine maker CSL says results of a Phase IIa trial of CSL112 in patients…

Cardio-vascularCSL LimitedCSL112PharmaceuticalResearch

Study finds cardiovascular risk from soluble medicines containing sodium

Study finds cardiovascular risk from soluble medicines containing sodium

28-11-2013

Thousands of patients taking effervescent and soluble medicines containing sodium are at greater cardiovascular…

Cardio-vascularHealthcarePharmaceuticalResearchUK

“Breakthrough Therapy” status for Portola’s andexanet alfa

25-11-2013

USA-based Portola Pharmaceuticals has been granted “Breakthrough Therapy” designation by the US Food…

andexanet alfaBayerBristol-Myers SquibbCardio-vascularEliquisNorth AmericaPharmaceuticalPortola PharmaceuticalsRegulationResearchXarelto

Amgen’s PCSK9 inhibitor evolocumab reduces cholesterol in Phase II study

Amgen’s PCSK9 inhibitor evolocumab reduces cholesterol in Phase II study

20-11-2013

USA-based biotech firm Amgen (Nasdaq: AMGN) has said its investigational PCSK9 inhibitor evolocumab helped…

AmgenBiotechnologyCardio-vascularevolocumabNorth AmericaResearchUSA

Daiichi Sankyo's edoxaban shows comparable efficacy to warfarin in Phase III trial

Daiichi Sankyo's edoxaban shows comparable efficacy to warfarin in Phase III trial

20-11-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) says that its blood thinner edoxaban met the primary efficacy…

Asia-PacificCardio-vascularDaiichi SankyoedoxabanPharmaceuticalResearchWarfarin Sodium

First human data show promise of Boehringer’s specific antidote for Pradaxa-induced anticoagulation

First human data show promise of Boehringer’s specific antidote for Pradaxa-induced anticoagulation

19-11-2013

Presented for the first time at the American Heart Association’s (AHA) Scientific Sessions, results…

BayerBoehringer IngelheimBristol-Myers SquibbCardio-vascularEliquisPharmaceuticalPradaxaResearchXarelto

FDA says PCSK9 inhibitors may not require outcome studies

FDA says PCSK9 inhibitors may not require outcome studies

18-11-2013

The US Food and Drug Administration has said that pharma companies developing PCSK9 inhibitors will not…

Cardio-vascularNorth AmericaPharmaceuticalRegulationUSA

AstraZeneca initiates two additional global studies with Brilinta

AstraZeneca initiates two additional global studies with Brilinta

14-11-2013

Anglo-Swedish drug major AstraZeneca plans to conduct two new clinical studies as part of PARTHENON,…

AstraZenecaBrilintaCardio-vascularPharmaceuticalResearch

40 to 64 of 519 results

Back to top